RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Open-Label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Clin. Cancer Res 2020 Oct 27;[EPub Ahead of Print], X Sheng, X Yan, L Wang, Y Shi, X Yao, H Luo, B Shi, J Liu, Z He, G Yu, J Ying, W Han, C Hu, Y Ling, Z Chi, C Cui, L Si, J Fang, A Zhou, J GuoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.